WallStSmart
A

Agilent Technologies Inc

NYSE: A · HEALTHCARE · DIAGNOSTICS & RESEARCH

$111.30
-3.11% today

Updated 2026-04-29

Market cap
$31.45B
P/E ratio
24.57
P/S ratio
4.45x
EPS (TTM)
$4.53
Dividend yield
0.87%
52W range
$104 – $160
Volume
2.3M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Agilent Technologies Inc (A) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$111.30
Consensus
$161.47
+45.08%
2030 Target
$415.73
+273.52%
DCF
$87.97
-46.53% MoS
16 analysts:
7 Buy3 Hold0 Sell

Management guidance

No specific CEO revenue targets found in available data. Management has not disclosed explicit revenue guidance for 2026-2030. Recent earnings calls mention 'strong core growth' and strategic expansion (Biocare acquisition, India expansion, digital pathology initiatives) but lack quantified revenue targets.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$692.88
$9.8B Rev × 20x P/S
Base case (2030)
$415.73
$9.8B Rev × 12x P/S
Bear case (2030)
$277.15
$9.8B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$6.8B$6.5B$6.9B$7.5B$8.0B$8.5B$9.1B$9.8B
Revenue growth—-4.7%6.7%8.4%6.2%6.8%6.9%6.9%
EPS$5.45$5.29$5.58$6.08$6.69$7.35$8.10$8.95
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$323.34$334.89$357.99$392.63$415.73

Catalysts & risks

Growth catalysts
+ Biocare Medical acquisition ($950M) expanding pathology/diagnostics portfolio
+ FDA approvals for PD-L1 companion diagnostics (8th indication achieved, precision oncology expansion)
+ Digital pathology platform launches (S540MD slide scanner, Cytation 9 imaging reader)
+ India market expansion (new Mumbai CEC) tapping emerging market growth
+ AI-integrated chromatography and automation solutions driving life sciences adoption
Key risks
- Near-term revenue miss (Q1 2026 missed estimates, impacted by US snowstorm disruption)
- Stock weakness YTD (-15.6%), suggesting execution concerns despite bullish analyst ratings
- P/E 25.5x elevated vs. sector, limited upside if growth disappoints
- China policy headwinds affecting biotech customer spending (sector-wide risk)
- Integration execution risk on $950M Biocare acquisition

Methodology

Agilent Technologies Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 16 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.